Home > Pulmonology > ATS 2022 > NAVIGATOR steers asthma patients to tezepelumab

NAVIGATOR steers asthma patients to tezepelumab

Presented By
Prof. Njira Lugogo, University of Michigan, MI, USA
Conference
ATS 2022
Trial
Phase 3, NAVIGATOR
Patients with severe, uncontrolled asthma demonstrated overall 2.8-fold higher odds of improved clinical responses to tezepelumab than placebo, including exacerbation reduction, better asthma control, improved lung function, and clinician assessment. Prof. Njira Lugogo (University of Michigan, MI, USA) presented a prespecified, on-treatment analysis of responses to tezepelumab using data from the completed phase 3, double-blind, placebo-controlled NAVIGATOR trial (NCT03347279) [1]. Participants aged 12–80 years were randomised to either receive subcutaneous injections of 210 mg tezepelumab (n=471) or subcutaneous placebo (n=449) every 4 weeks for 52 weeks, while continuing to take their medium- or high-dose corticosteroid inhalers and at least one other asthma-control medication during the study. The primary endpoint ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on